A61K 9/284
Obtained by reactions only involving carbon-to-carbon unsaturated bonds
Official title: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone}
A61K9/284 (Obtained by reactions only involving carbon-to-carbon unsaturated bonds) appears on 1,316 US grants and 2,562 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,316
- Published applications
- 2,562
- Assignees
- 894
- Inventors
- 3,603
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 3 | 0 |
| 1977 | 1 | 0 |
| 1978 | 2 | 0 |
| 1979 | 0 | 0 |
| 1980 | 1 | 0 |
| 1981 | 2 | 0 |
| 1982 | 1 | 0 |
| 1983 | 2 | 0 |
| 1984 | 6 | 0 |
| 1985 | 5 | 0 |
| 1986 | 3 | 0 |
| 1987 | 6 | 0 |
| 1988 | 5 | 0 |
| 1989 | 6 | 0 |
| 1990 | 3 | 0 |
| 1991 | 5 | 0 |
| 1992 | 4 | 0 |
| 1993 | 3 | 0 |
| 1994 | 5 | 0 |
| 1995 | 4 | 0 |
| 1996 | 11 | 0 |
| 1997 | 11 | 0 |
| 1998 | 8 | 0 |
| 1999 | 9 | 0 |
| 2000 | 20 | 0 |
| 2001 | 12 | 8 |
| 2002 | 17 | 25 |
| 2003 | 19 | 61 |
| 2004 | 19 | 85 |
| 2005 | 13 | 90 |
| 2006 | 10 | 80 |
| 2007 | 13 | 72 |
| 2008 | 17 | 80 |
| 2009 | 20 | 98 |
| 2010 | 37 | 114 |
| 2011 | 28 | 97 |
| 2012 | 41 | 99 |
| 2013 | 77 | 142 |
| 2014 | 96 | 161 |
| 2015 | 76 | 162 |
| 2016 | 87 | 136 |
| 2017 | 99 | 145 |
| 2018 | 62 | 114 |
| 2019 | 63 | 133 |
| 2020 | 76 | 110 |
| 2021 | 75 | 117 |
| 2022 | 55 | 104 |
| 2023 | 50 | 95 |
| 2024 | 62 | 91 |
| 2025 | 40 | 79 |
| 2026 | 26 | 64 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Dosage forms for TYK2 inhibitors6 Oct 2026US 12,751,948 B2Bristol-Myers Squibb Company
- Soluble pharmaceutical compositions comprising salts of disubstituted 1, 2, 4-triazine compound22 Sep 2026US 12,740,987 B2Mineralys Therapeutics, Inc.
- Extended release amphetamine tablets15 Sep 2026US 12,734,132 B2Tris Pharma, Inc.
- Dosage forms for Tyk2 inhibitors15 Sep 2026US 12,734,169 B2Bristol-Myers Squibb Company
- Compositions for modulating gut microflora populations, enhancing drug potency and treating cancer, and methods for making and using same25 Aug 2026US 12,714,730 B2Persephone Biosciences, Inc.
- Method and pharmaceutical composition for treating a sleep disorder8 Oct 2026US 2026/0306442 A1Overseas Pharmaceuticals, Ltd.
- Methods of treating erythropoietic protoporphyria or x-linked protoporphyria with bitopertin1 Oct 2026US 2026/0294899 A1Disc Medicine, Inc.
- Enriched Withania somnifera Based Dietary Composition and a Method Thereof24 Sep 2026US 2026/0284137 A1Arjuna Natural Private Limited
- Methods and compositions for improving exercise performance, single ventricular performance, cardiac output and myocardial performance index (mpi) in single ventricular heart disease, using udenafil compositions3 Sep 2026US 2026/0256791 A1Mezzion Pharma Co., Ltd.
- Formulations of (+)-2-[1-(3-ethoxy-4- methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione27 Aug 2026US 2026/0248727 A1Amgen Inc.
Most cited
By later US patents
- Controlled release formulations coated with aqueous dispersions of acrylic polymers1,011US 5,639,476 AEuro-Celtique S. A. · 1997
- Sustained release drug delivery devices481US 5,378,475 AUniversity of Kentucky Research Foundation · 1995
- Orally administrable opioid formulations having extended duration of effect437US 5,968,551 APurdue Pharma L. P. · 1999
- Stabilized controlled release formulations having acrylic polymer coating434US 5,286,493 AEuroceltique, S.A. · 1994
- Controlled release formulations coated with aqueous dispersions of acrylic polymers428US 5,580,578 AEuro-Celtique S. A. · 1996